Subscribe

China Traditional Chinese Medicine Holdings Co. Limited (0570.HK)

HKD1.50 +0.05 (+3.45%)
HK HKSE Healthcare Drug Manufacturers - Specialty & Generic
Address Emperor Group Centre
Wan Chai, HK
CEO Jun Yang
Website china-tcm.com.cn
IPO 1993-04-07
ISIN HK0000056256

Explore sections of this company profile

Also trades on Hong Kong Stock Exchange · 0570.HK (HKD) Other OTC · CHIZF (USD)
Description

China Traditional Chinese Medicine Holdings Co. Limited functions as an investment holding company, primarily focusing on the research, development, and sale of traditional Chinese medicine and other pharmaceutical goods across the People's Republic of China. The company's product range includes medicinal granules, finished pharmaceutical preparations, pre-portioned decoction materials, and various healthcare products. Furthermore, its operations extend to the cultivation and management of Chinese medicinal herbs, the manufacturing of traditional Chinese medicines, and the trading of pharmaceutical products. It also delivers marketing, advertising, and consulting services related to TCM, and operates retail outlets for pharmaceuticals and decoction products. Property leasing services represent another facet of its business. The company distributes its products to healthcare facilities and retail pharmacies. Established in 1573 and headquartered in Wan Chai, Hong Kong, the firm was formerly known as China Traditional Chinese Medicine Co. Limited before adopting its current name in July 2016.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD1.50 +0.05 (+3.45%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
13M
Beta
0.71
Float Shares
3.35B
Free Float %
66.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.96% -2.50% -7.69% -22.77% -33.05% -25.36% -30.97% -59.69% -68.86% -55.43% +183.64%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1.50
DCF (Unlevered) 7.32 +387.7%
DCF (Levered) 4.14 +176.2%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 0% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 0 0
Hold 1 0
Sell 1 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.24
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -10.7% Q4'25: -17.4% (vs Q4'23)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    -734.6% Q4'25: -133.2% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +10.7% Q4'25: +11.5% (vs Q4'23)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +2.1% Q4'25: +1.7% (vs Q4'23)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +1.6% Q4'25: +2.5% (vs Q4'23)
  • ✓
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.0% Q4'25: +0.0% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    1.76× ★ Q4'25: 0.90× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.74) × ERP
WACC = 73% × Ke + 27% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 7.34 Current price: 1.50
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
2 Rev. Ana.
2 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
3.71B
est: 4.50B (-17.6%)
6.53B
est: 7.34B (-10.9%)
8.34B
est: 9.70B (-14.1%)
11.26B
est: 12.60B (-10.6%)
14.32B
est: 15.71B (-8.9%)
14.81B
est: 17.40B (-14.9%)
19.05B
est: 22.74B (-16.2%)
14.30B
est: 16.35B (-12.5%)
18.12B
est: 20.69B (-12.4%)
16.51B
est: 15.01B (+10.0%)
14.74B
est: 14.03B (+5.1%)
14.91B
14.77B – 15.05B
+6.3% YoY
15.26B
14.98B – 15.55B
+2.4% YoY
16.08B
15.93B – 16.23B
+5.3% YoY
EBITDA
921.02M
est: 724.65M (+27.1%)
1.71B
est: 1.18B (+45.2%)
2.19B
est: 1.56B (+40.5%)
2.66B
est: 2.03B (+31.2%)
3.05B
est: 2.53B (+20.5%)
3.16B
est: 2.80B (+12.9%)
3.59B
est: 3.66B (-1.8%)
2.16B
est: 2.63B (-17.9%)
2.56B
est: 3.33B (-23.2%)
1.82B
est: 2.06B (-11.6%)
1.42B
est: 1.93B (-26.5%)
2.05B
2.03B – 2.07B
+6.3% YoY
2.10B
2.06B – 2.14B
+2.4% YoY
2.21B
2.19B – 2.23B
+5.3% YoY
EBIT
759.34M
est: 458.79M (+65.5%)
1.38B
est: 747.27M (+84.3%)
1.79B
est: 988.40M (+80.9%)
2.15B
est: 1.28B (+67.5%)
2.46B
est: 1.60B (+53.4%)
2.47B
est: 1.77B (+39.6%)
2.74B
est: 2.32B (+18.4%)
1.06B
est: 1.67B (-36.3%)
1.42B
est: 2.11B (-32.5%)
751.90M
est: 1.09B (-31.1%)
315.61M
est: 1.02B (-69.1%)
1.08B
1.07B – 1.09B
+6.3% YoY
1.11B
1.09B – 1.13B
+2.4% YoY
1.17B
1.16B – 1.18B
+5.3% YoY
Net Income
621.69M
est: 1.01B (-38.6%)
966.93M
est: 1.20B (-19.4%)
1.17B
est: 1.55B (-24.7%)
1.44B
est: 1.73B (-16.9%)
1.59B
est: 1.88B (-15.7%)
1.66B
est: 1.87B (-10.9%)
1.93B
est: 2.57B (-24.7%)
764.49M
est: 880.96M (-13.2%)
1.29B
est: 1.41B (-9.0%)
54.07M
est: 151.02M (-64.2%)
-342.07M
est: -427.87M (+20.1%)
731.20M
722.23M – 740.16M
+270.9% YoY
835.69M
749.28M – 922.11M
+14.3% YoY
940.13M
928.60M – 951.67M
+12.5% YoY
SGA
1.47B
est: 1.86B (-21.1%)
2.30B
est: 3.03B (-24.1%)
2.79B
est: 4.01B (-30.5%)
3.42B
est: 5.20B (-34.3%)
5.11B
est: 6.49B (-21.3%)
6.29B
est: 7.19B (-12.4%)
8.56B
est: 9.39B (-8.9%)
5.55B
est: 6.75B (-17.8%)
7.45B
est: 8.55B (-12.9%)
6.48B
est: 6.16B (+5.1%)
6.07B
est: 5.76B (+5.4%)
6.12B
6.06B – 6.18B
+6.3% YoY
6.26B
6.15B – 6.38B
+2.4% YoY
6.60B
6.54B – 6.66B
+5.3% YoY
EPS
0.17
est: 0.20 (-15.4%)
0.22
est: 0.24 (-7.6%)
0.26
est: 0.31 (-15.8%)
0.30
est: 0.34 (-12.7%)
0.32
est: 0.37 (-14.5%)
0.33
est: 0.37 (-10.9%)
0.38
est: 0.51 (-25.4%)
0.15
est: 0.17 (-14.3%)
0.26
est: 0.28 (-7.3%)
0.01
est: 0.03 (-64.3%)
-0.07
est: -0.08 (+20.1%)
0.15
0.14 – 0.15
+270.9% YoY
0.17
0.15 – 0.18
+14.3% YoY
0.19
0.18 – 0.19
+12.5% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-28 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-27 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-26 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-22 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-21 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-20 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-19 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-18 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-15 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-14 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-13 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-12 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-11 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-08 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-07 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-06 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-05 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-05-04 B 3/5 5/5 1/5 1/5 3/5 1/5 5/5
2026-04-30 B- 2/5 4/5 1/5 1/5 2/5 1/5 5/5
2026-04-29 B- 2/5 4/5 1/5 1/5 2/5 1/5 5/5
2026-04-28 B- 2/5 4/5 1/5 1/5 2/5 1/5 5/5
2026-04-27 B- 2/5 4/5 1/5 1/5 2/5 1/5 5/5
2026-04-24 B- 2/5 4/5 1/5 1/5 2/5 1/5 5/5
2026-04-23 B- 2/5 4/5 1/5 1/5 2/5 1/5 5/5
2026-04-22 B- 2/5 4/5 1/5 1/5 2/5 1/5 5/5
2026-04-21 B- 2/5 4/5 1/5 1/5 2/5 1/5 5/5
2026-04-20 B- 2/5 4/5 1/5 1/5 2/5 1/5 5/5
2026-04-17 B- 2/5 4/5 1/5 1/5 2/5 1/5 5/5
2026-04-16 B- 2/5 4/5 1/5 1/5 2/5 1/5 5/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
278.92M
OE per share TTM
0.06
Owner's Yield
3.55%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
47.7%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 72 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares MSCI China Small-Cap ETF ECNS 0.34% 219.0K 0.59%
2 iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L 0.05% 36.5K 0.74%
3 State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L 0.05% 293.9K 0.55%
4 FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE 0.05% 162.7K 0.58%
5 Avantis Emerging Markets Small Cap Equity ETF AVEE 0.03% 39.5K 0.42%
6 iShares MSCI EM Small Cap UCITS ETF IEMS.L 0.03% 111.2K 0.74%
7 iShares MSCI Emerging Markets Small-Cap ETF EEMS 0.03% 111.1K 0.72%
8 State Street SPDR S&P International Small Cap ETF GWX 0.03% 241.5K 0.40%
9 Franklin FTSE China ETF FLCH 0.03% 72.3K 0.19%
10 Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L 0.02% 53.0K 0.35%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
18.8K
Shares Outstanding
5.04B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Jun Yang Executive Chairman 1M male
Hongjian Li President & Executive Director 1M male
Peng Li Executive Director 594.0K male
Lixin Shen Vice President & Financial Director — male
Sau Mei Ng ACIS FCIS Company Secretary — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic